Trial Profile
Post-Marketing Observational Study to Evaluate Safety Profile of Flixotide 50 μg pMDI Treatment in Chinese Subjects With Asthma Aged 1-<4 Years
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 03 Oct 2018 Status changed from recruiting to completed.
- 10 May 2018 Planned End Date changed from 30 Sep 2018 to 1 Oct 2018.
- 10 May 2018 Planned primary completion date changed from 30 Sep 2018 to 1 Oct 2018.